Clinuvel is making progress in developing sustained-release liquid drug formulations through its preclinical program. Results show the potential of depot formulations to extend the release duration of peptide-based drugs. The company’s strategy aims to maintain detectable peptide levels in the bloodstream over longer periods, enhancing patient exposure while reducing dosing frequency. The technology could be a versatile platform for delivering a range of peptides, starting with melanocortins. Clinuvel expects to finish evaluating its first formulations in the second half of 2026, with injection volumes tailored to body weight for flexible dosing options.

Read more at Nasdaq.: Clinuvel Advances Sustained-Release Peptide Formulations In Preclinical Program